Phoenix Biotech Acquisition Corp. Unit
PBAXU
PBAXU was delisted on the 7th of February, 2024.
1 hedge funds and large institutions have $1.83K invested in Phoenix Biotech Acquisition Corp. Unit in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $1.07M → $1.83K (-$1.07M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$1.07M |
PBAXU Hedge Fund Activity: Q2 2023 in Review
1 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q2 2023, worth a combined $1.83K — down 100% from $1.07M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PBAXU and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Yakira Capital Management, exiting entirely with an estimated $1.07M sold.
- 1 institutional investor held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $1.83K of Phoenix Biotech Acquisition Corp. Unit stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Phoenix Biotech Acquisition Corp. Unit positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Phoenix Biotech Acquisition Corp. Unit seller in Q2 2023 was Yakira Capital Management, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2023.